Boiler Room: The Official Stock Market Discussion

K

KING WILL

Superstar
Joined
Jun 14, 2018
Messages
8,761
Reputation
1,362
Daps
22,738
Any1 messing w/ WDAY?

2 years in a row Fortune ranked them #1 for growth.

Just added a lil in my daughters account.

$165 right now, PT of $214. And about a year ago it was $135. 52 wk high of $226.
 
N.J.stan

N.J.stan

RIP Mac Miller
Joined
Apr 5, 2014
Messages
4,853
Reputation
870
Daps
11,261
Reppin
NJ
Annnnd there go all my gains for the week, thanks Uber :stopitslime:

Time to avg :mjlit:
 
88m3

88m3

Fast Money & Foreign Objects
Joined
May 21, 2012
Messages
89,301
Reputation
3,727
Daps
159,030
Reppin
Brooklyn
Bloomberg
·
BREAKING: A glitch in the Robinhood app is allowing users to trade stocks with what amounts to free money. One trader bragged about a $1 million position funded by a $4,000 deposit.


About this website

BLOOMBERG.COM

Robinhood Traders Discovered a Glitch That Gave Them Access to ‘Free Money’
Robinhood is “aware of the isolated situations and communicating directly with customers,” spokesperson Lavinia Chirico said in an email response to questions.


this should be interesting

@Domingo Halliburton @Futuristic Eskimo
 
A

analog

Superstar
Joined
Jun 21, 2012
Messages
5,444
Reputation
1,192
Daps
21,761
Reppin
Toronto
Domingo Halliburton said:
Martin Shkreli posted this on his blog in August:
"The next five or ten years of biopharma investing is basically all about gene therapy. After AVXS, who knows what is possible. Abeona (ABEO), Axovant (AXON), Audentes (BOLD), BioMarin (BMRN), Oxford, PTC (PTCT), Spark (ONCE), UniQure (QURE), Rocket (RCKT), Sangamo (SGMO), RGNX, Sarepta (SRPT), Solid (SLDB), Ultragenyx (RARE), Voyager (VYGR) are all players. My guess is an equal-weighted or capitalization-weighted index of the above would outperform pretty much any other index. "

Spark just got bought for a 120% premium.

He's also very bullish on GBT.

I'd have to look deeper into it but there's some compelling names there.
Click to expand...
Have some cash, and don't feel comfortable re-upping on my long term funds as they're all near 52-week highs.

I might roll the dice on a handful of these high cap stocks as they're mostly trading at a ~50% discount from their 52-week highs.
 
K

KING WILL

Superstar
Joined
Jun 14, 2018
Messages
8,761
Reputation
1,362
Daps
22,738
That's a $15 billion per-year commercial opportunity right now -- based on the drug's estimated annual net price of $1,625, per the cost-effectiveness watchdog ICER. Future price hikes, combined with the continued growth of this target market as a whole, though, could push Vascepa's sales into truly rarefied air.


Keeping with this theme, Vascepa has the potential to generate annual sales larger than those of Pfizer's (NYSE: PFE) megablockbuster cholesterol medicine Lipitor, as well as AbbVie's anti-inflammatory behemoth Humira. For those new to the world of biopharma, Lipitor and Humira are the two bestselling pharmaceutical products of all time. That's just how big of a deal Vascepa's proposed cardioprotective indication is from a commercial standpoint.


Amarin's Stock Could Reach $50 Per Share Soon | Nasdaq​
 
You must log in or register to reply here.
Top